Company: GRCE
Filing Date: 2025-02-10
Form Type: 8-K
Source: 0001140361-25-003645
Chunk: 0

Company: Grace Therapeutics, Inc.
Filing Date: 2025-02-10
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01.      Entry into a Material Definitive Agreement.  

Private Placement Offering

On February 10, 2025, Grace Therapeutics, Inc. (the “ Company”), in connection with a private placement offering of the Company’s securities (the
“ Offering”), entered into with certain institutional and accredited investors (the “ Investors”) (i) a securities purchase agreement involving a placement agent (the “ Placement Agent Purchase Agreement”), (ii) a securities purchase agreement not
involving a placement agent (the “ Non-Placement Agent Purchase Agreement” and, together with the Placement Agent Purchase Agreement, the “ Purchase Agreements”), and (iii) a registration rights agreement (the “ Registration Rights Agreement”).

Pursuant to the Purchase Agreements, the Company agreed to offer and sell in the Offering an aggregate of3,252,132shares of common stock, par value $0.0001 (the “ Common Stock”), of the Company (the “ Shares”) at a purchase price of $3.395 per share of Common Stock and pre-funded warrants (the “ Pre-Funded Warrants”) to
purchase up to1,166,160shares of Common Stock (the “ Pre-Funded Warrant Shares”) at a purchase price equal to the purchase price per Share less $0.0001. Each Pre-Funded Warrant
will be exercisable for one Pre-Funded Warrant Share at an exercise price of $0.0001 per Pre-Funded Warrant Share, will be immediately exercisable and will expire once exercised in full.

Pursuant to the Purchase Agreements, for each Share and each Pre-Funded Warrant issued in
the Offering, the Company agreed to issue to the purchaser thereof an accompanying common warrant (the “ Common Warrants” and, together with the Pre-Funded Warrants, the “ Warrants”) to purchase shares of Common Stock(or Pre-Funded Warrants in lieu thereof), exercisable for an aggregate of4,418,292 shares of Common Stock(or Pre-Funded Warrants
in lieu thereof)(the “ Common Warrant Shares” and, together with the Pre-Funded Warrant Shares, the “ Warrant Shares”). Each Common Warrant is exercisable for
one Common Warrant Share at an exercise price of $3.395 per Common Warrant Share(or one Pre-Funded Warrant at an exercise price of $3.3949 per Pre-Funded Warrant in lieu
thereof), will be immediately exercisable and will